Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Approved for Phase 3!?

<< Previous

Bullboard Posts

Next >>

Comment by Cookie2018on Nov 04, 2020 4:23pm

140 Views

Post# 31837061

RE:Approved for Phase 3!?

I sent them an email 2 days ago asking them to validate it before I share with social media. They have not responsed back to me as of yet, so not sure if something leaked or there are delays in sedar/news releases or bogus article, but I did find it on another site too....time will tell.

<< Previous

Bullboard Posts

Next >>

Three stocks with strong income statements to buy right now